Bosentan

Product Name: Bosentan
CAS No.: 147536-97-8
Chemical Name: Bosentan
Synonyms: Bosentan USP/EP/BP;BOSENTAN;Actelion;ro47-0203;ro47-0203/039;Bosentan 13C6;Bosentan impurity;bosentan , CID 104865;2’-bipyrimidin)-4-yl)-enoxy)(;Bosentan (Benzenesulfonamide)
CBNumber: CB3425624
Molecular Formula: C27H29N5O6S
Formula Weight: 551.61
MOL File: 147536-97-8.mol

More

Less

Bosentan Property

Melting point:: 107-110°C
Boiling point:: 742.3±70.0 °C(Predicted)
Density: 1.325±0.06 g/cm3(Predicted)
storage temp.: -20°C Freezer
solubility: DMSO (Slightly), Methanol (Slightly)
form: Solid
pka: 4.01±0.10(Predicted)
color: White to Pale Yelloow
CAS DataBase Reference: 147536-97-8(CAS DataBase Reference)

More

Less

Safety

HS Code: 29350090

More

Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Danger

Hazard statements

H302Harmful if swallowed

H360May damage fertility or the unborn child

H410Very toxic to aquatic life with long lasting effects

Precautionary statements

P273Avoid release to the environment.

P281Use personal protective equipment as required.

More

Less

N-Bromosuccinimide Price

Cayman Chemical

Product number: 11731
Product name: Bosentan
Purity: ≥98%
Packaging: 5mg
Price: $33
Updated: 2024/03/01

Cayman Chemical

Product number: 11731
Product name: Bosentan
Purity: ≥98%
Packaging: 10mg
Price: $62
Updated: 2024/03/01

Cayman Chemical

Product number: 11731
Product name: Bosentan
Purity: ≥98%
Packaging: 50mg
Price: $112
Updated: 2024/03/01

Tocris

Product number: 6232
Product name: Bosentan
Purity: ≥98%(HPLC)
Packaging: 10
Price: $75
Updated: 2021/12/16

Tocris

Product number: 6232
Product name: Bosentan
Purity: ≥98%(HPLC)
Packaging: 50
Price: $324
Updated: 2021/12/16

More

Less

Bosentan Chemical Properties,Usage,Production

Description

Bosentan was introduced in the US as a twice-daily oral treatment for pulmonary arterial hypertension. It can be synthesized in five steps via condensation of diethyl (2- methoxyphenoxy)malonate with pyrimidine-2-carboxamidine to give the precursor of the symmetrical central dichloropyrimidine ring which is then successively treated with the potassium salt of 4-tert-butylbenzenesulfonamide and the sodium salt of ethylene gycol. Bosentan is the first endothelin (ET) receptor antagonist to be launched. ET-1, the most potent endogenous vasoconstrictor known, has been demonstrated to play a major role in the functional and structural changes observed in pulmonary hypertension. Bosentan is a mixed ET_A and ET_B receptor antagonist that inhibits the pulmonary arterial vasoconstricting effect of ET-1 predominantly mediated via ET_A receptors on smooth muscle cells. In a hypoxia-induced model of pulmonary hypertension in rat, it reduced the development of pulmonary hypertension as well as right ventricular hypertrophy and prevented pulmonary arterial remodeling. In clinical trials, patients treated with bosentan showed a 20% increase in exercise capacity compared to placebo as measured by the six minute walk test. Bosentan not only improved the distance walked by patients but also significantly decreased mean pulmonary artery pressure, mean pulmonary vascular resistance, mean capillary wedge pressure and mean right atrial pressure. It demonstrated a beneficial selectivity for the pulmonary vasculature since it had no significant effect on mean aortic blood pressure and systolic vascular resistance. The compound is hepatically metabolized into three major metabolites by CYP3A4 and 2C9 and almost exclusively eliminated in the bile. Although large interspecies differences in systemic plasma clearance was observed (1.5 mL/min/kg in dogs to 72 mL/min/kg in rabbits), a satisfactory systemic clearance (2 mL/min/kg) was measured in human. The most frequent adverse effect was reversible elevation of liver transaminases. This adverse reaction appears to be due to intracellular accumulation of cytotoxic bile salts resulting from inhibition of the hepatocanalicular bile salt export pump by bosentan.

Chemical Properties

Pale Yellow to Off-White Solid

Originator

Roche (Switzerland)

Uses

Bosentan is a mixed endothelin receptor antagonist. Used as a vasodilator. Antihypertensive.

Uses

A mixed endothelin receptor antagonist. Used as a vasodilator. Antihypertensive.

Definition

ChEBI: Bosentan is a sulfonamide, a member of pyrimidines and a primary alcohol. It has a role as an antihypertensive agent and an endothelin receptor antagonist.

Manufacturing Process

4-t-butyl-N-[6-chloro-5-(2-methoxyphenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4- yl]benzenesulphonamide were heated to 100°C, cooled for a further 4 hours, poured on to ice and adjusted to pH 3 with 1 M tartaric acid. The suspension obtained was extracted with ethyl acetate, the organic extracts were combined, washed with water, dried with sodium sulfate and concentrated under reduced pressure. The residue was chromatographed on silica gel with CH2Cl2-ethyl acetate 9:1 and yielded 4-t-butyl-N-[6-(2-hydroxyethoxy)-5-(2- methoxyphenoxy)-2-(pyrimidin-2-yl)-pyrimidin-4-yl]benzenesulphonamide as a solid. Sodium salt melted at 195°-198°C.
The 4-t-butyl-N-[6-chloro-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl)-pyrimidin- 4-yl]benzenesulfonamide was prepared starting from pyrimidine-2- carboxamidine hydrochloride via rac-5-(2-methoxyphenoxy)-2-(pyrimidin-2- yl)tetrahydropyrimidine-4,6-dione and 4,6-dichloro-5-(2-methoxyphenoxy)- 2,2'-bipyrimidine.

brand name

Tracleer (Actelion).

Therapeutic Function

Endothelin receptor antagonist

General Description

Bosentan, N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tertbutyl-benzenesulfonamide (Tracleer, Bozentan), was thefirst endothelin receptor antagonist marketed in the UnitedStates. Bosentan works by competitively blocking the endothelinreceptor subtypes ETA and ETB. In binding to thereceptors, it blocks the effects of endothelin, which includeconstriction of the vascular smooth muscle, which leads tonarrowing of the blood vessels and hypertension. Althoughit is not selective for the ETA receptors, it does have a higheraffinity for that subtype over ETB. However, the clinical significanceof selectivity over preferential receptor bindinghas not been demonstrated. Bosentan is an inducer ofCYP2C9 and CYP3A4, and patients using bosentan must bemonitored for liver toxicity.

Hazard

A reproductive hazard.

Pharmacokinetics

Bosentan is mainly eliminated from the body by hepatic metabolism and subsequent biliary excretion of the metabolites. Three metabolites have been identified, formed by CYP2C9 and CYP3A4. The pharmacokinetics of bosentan are dose-proportional up to 500 mg/day (multiple doses). The pharmacokinetics of bosentan in pediatric patients with PAH are comparable to those in healthy subjects, whereas adult patients with PAH show a twofold increase in clearance. Severe renal impairment and mild hepatic impairment do not have a clinically relevant influence on its pharmacokinetics. Bosentan generally should be avoided in patients with moderate or severe hepatic impairment and/or elevated liver aminotransferases. Inhibitors of CYP3A4 increase the plasma concentration of bosentan as well as cause an increase in the clearance of drugs metabolized by CYP3A4 and CYP2C9 because of induction of these metabolizing enzymes. The possibility of reduced efficacy of CYP2C9 and CYP3A4 substrates coadministered with bosentan is increased. No clinically relevant interaction was detected for P-glycoprotein. Bosentan can increase plasma levels of ET-1.

Clinical Use

Bosentan is an orally administered, nonselective ET-1 receptor antagonist blocking ETA and ETB receptors and is approved for the treatment of patients with PAH. Following oral administration, bosentan attains peak plasma concentrations in approximately 3 hours, with an absolute bioavailability of approximately 50%. Food has no clinically relevant effect on its absorption recommended doses. Bosentan is approximately 98% bound to albumin, with a volume of distribution of 30 L. Its terminal half-life after oral administration is 5.4 hours and is unchanged at steady state.

Side effects

Adverse effects include hypotension, headache, flushing, increased liver aminotransferases, leg edema, and anemia. Bosentan may cause birth defects and, therefore, is contraindicated in pregnancy. It also can cause liver injury.

Drug interactions

Potentially hazardous interactions with other drugs Antibacterials: concentration reduced by rifampicin - avoid. Antidiabetics: increased risk of hepatoxicity with glibenclamide - avoid. Antifungals: fluconazole, ketoconazole and itraconazole cause large increases in concentration of bosentan - avoid. Antivirals: concentration of bosentan increased by lopinavir and ritonavir - consider reducing bosentan dose; telaprevir concentration reduced and bosentan concentration possibly increased; avoid with tipranavir. Ciclosporin: When ciclosporin and bosentan are co-administered, initial trough concentrations of bosentan are 30 times higher than normal. At steady state, trough levels are 3-4 times higher than normal. Blood concentrations of ciclosporin decreased by 50% - avoid. Cytotoxics: concentration of bosutinib possibly reduced - avoid. Guanfacine: concentration of guanfacine possibly reduced - increase guanfacine dose. Lipid lowering agents: concentration of simvastatin reduced by 45% - monitor cholesterol levels and adjust dose of statin. Oestrogens, progestogens and ulipristal: may be failure of contraception - use alternative method.

Metabolism

Upon multiple dosing, plasma concentrations of bosentan decrease gradually to 50%-65% of those seen after single dose administration. This decrease is probably due to auto-induction of metabolising liver enzymes. Steadystate conditions are reached within 3-5 days. Bosentan is eliminated by biliary excretion following metabolism in the liver by the cytochrome P450 isoenzymes, CYP2C9 and CYP3A4. Bosentan forms three metabolites and only one of these is pharmacologically active. This metabolite is mainly excreted unchanged via the bile. In adult patients, the exposure to the active metabolite is greater than in healthy subjects. In patients with evidence of the presence of cholestasis, the exposure to the active metabolite may be increased.

storage

Store at +4°C

Bosentan Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

Bosentan Suppliers

Canada 3 China 189 Europe 2 Germany 3 India 19 South Korea 1 United Kingdom 6 United States 31 Global 254

LGM Pharma

Tel: 1-(800)-881-8210
Fax: 615-250-9817
Email: inquiries@lgmpharma.com
Country: United States
ProdList: 2123
Advantage: 70

MedChemexpress LLC

Tel: 021-58955995
Fax: 609-228-5909
Email: sales@medchemexpress.cn
Country: United States
ProdList: 4861
Advantage: 58

AdooQ BioScience, LLC

Tel: +1 (866) 930-6790
Fax: +1 (866) 333-9607
Email: info@adooq.com
Country: United States
ProdList: 2782
Advantage: 58

Target molecule Corp.

Tel: 857-239-0968
Fax: 857-239-8801
Email: service1@targetmol.com
Country: United States
ProdList: 2559
Advantage: 60

Musechem

Tel: +1-800-259-7612
Fax: +1-800-259-7612
Email: info@musechem.com
Country: United States
ProdList: 4660
Advantage: 60

TargetMol Chemicals Inc.

Tel: +1-781-999-5354 +1-00000000000
Email: marketing@targetmol.com
Country: United States
ProdList: 32165
Advantage: 58

InvivoChem

Tel: +1-708-310-1919 +1-13798911105
Fax: 708-557-7486
Email: sales@invivochem.cn
Country: United States
ProdList: 6391
Advantage: 58

Aladdin Scientific

Tel: +1-+1(833)-552-7181
Email: sales@aladdinsci.com
Country: United States
ProdList: 52925
Advantage: 58

TargetMol Chemicals Inc.

Tel
Email: support@targetmol.com
Country: United States
ProdList: 38632
Advantage: 58

ApexBio Technology

Tel: --
Fax: --
Email: sales@apexbt.com
Country: United States
ProdList: 6251
Advantage: 58

Alfa Chemistry

Tel: --
Fax: --
Email: info@Alfa-Chemistry.com
Country: United States
ProdList: 6814
Advantage: 0

SynFine Research

Tel: --
Fax: --
Email: research@synfine.com
Country: United States
ProdList: 1024
Advantage: 68

Acanthus Research

Tel: --
Fax: --
Email: inquiries@acanthusresearch.com
Country: United States
ProdList: 46
Advantage: 50

Cayman Chemical Company

Tel: --
Fax: --
Email: cayman@caymanchem.com
Country: United States
ProdList: 6213
Advantage: 81

MedChemExpress

Tel: --
Fax: --
Email: sales@medchemexpress.com
Country: United States
ProdList: 6398
Advantage: 58

MYLAN LABORATORIES LTD

Tel: --
Fax: --
Email: info@amstock.com
Country: United States
ProdList: 179
Advantage: 58

Frontier Scientific, Inc.

Tel: --
Fax: --
Email: sales@frontiersci.com
Country: United States
ProdList: 6222
Advantage: 86

Matrix Scientific

Tel: --
Fax: --
Email: sales@matrixscientific.com
Country: United States
ProdList: 6632
Advantage: 80

Focus Synthesis LLC

Tel: --
Fax: --
Email: acd@focussynthesis.com
Country: United States
ProdList: 2487
Advantage: 61

Ivy Fine Chemicals

Tel: --
Fax: --
Email: sales@ivychem.com
Country: United States
ProdList: 6493
Advantage: 58

Santa Cruz Biotechnology, Inc.

Tel: --
Fax: --
Email: scbt@scbt.com
Country: United States
ProdList: 3597
Advantage: 60

Tecoland Corporation

Tel: --
Fax: --
Email: info@tecoland.com
Country: United States
ProdList: 275
Advantage: 50

Waterstone Technology, LLC

Tel: --
Fax: --
Email: sales@waterstonetech.com
Country: United States
ProdList: 6786
Advantage: 30

AlliChem, LLC

Tel: --
Fax: --
Email: sales@allichemllc.com
Country: United States
ProdList: 6516
Advantage: 60

2A PharmaChem USA

Tel: --
Fax: --
Email: sales@2apharmachem.com
Country: United States
ProdList: 6137
Advantage: 39

3B Scientific Corporation

Tel: --
Fax: --
Email: sales@3bsc.com
Country: United States
ProdList: 6718
Advantage: 47

AK Scientific, Inc.

Tel: --
Fax: --
Email: sales@aksci.com
Country: United States
ProdList: 6347
Advantage: 65

APAC Pharmaceutical, LLC

Tel: --
Fax: --
Email: sales@apacpharma.com
Country: United States
ProdList: 6322
Advantage: 38

BOSCHE SCIENTIFIC, LLC

Tel: --
Fax: --
Email: Sales@BoscheSci.com
Country: United States
ProdList: 6477
Advantage: 55

ChemPacific Corporation

Tel: --
Fax: --
Email: sales@chempacific.com
Country: United States
ProdList: 6891
Advantage: 51

American Custom Chemicals Corporation

Tel: --
Fax: --
Email: sales@acccorporation.com
Country: United States
ProdList: 6820
Advantage: 51

More

Less

View Lastest Price from Bosentan manufacturers

Zhuozhou Wenxi import and Export Co., Ltd

Product: Bosentan 147536-97-8
Price: US $15.00-10.00/KG
Min. Order: 1KG
Purity: 99%+ HPLC
Supply Ability: Monthly supply of 1 ton
Release date: 2021-07-10

Zhuozhou Wenxi import and Export Co., Ltd

Product: Bosentan 147536-97-8
Price: US $15.00-10.00/KG
Min. Order: 1KG
Purity: 99%+ HPLC
Supply Ability: Monthly supply of 1 ton
Release date: 2021-07-08

Career Henan Chemical Co

Product: Bosentan 147536-97-8
Price: US $1.00/KG
Min. Order: 1G
Purity: 98%
Supply Ability: 100KG
Release date: 2018-08-20

147536-97-8, BosentanRelated Search:

p-Anisidine Guaiacol 4-Methoxyphenol 4-Methoxybenzyl cyanide p-Anisaldehyde Ethoxyquin Anisole (Trifluoromethoxy)benzene 2-Cyanopyrimidine 5-(2-Methoxyphenoxy)-[2,2'-bipyrimidine]-4,6(1H,5H)-dione 2-(2-Methoxyphenoxy)propanedioic acid diethyl ester Bosentan Impurity 1 Diethyl chloromalonate Bosentan Impurity 5 Bosentan Impurity 17 Bosentan Impurity 7 Bosentan Impurity 2 Bosentan Impurity

2’-bipyrimidin)-4-yl)-enoxy)(

benzenesulfonamide,4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyph

ro47-0203

4-(tert-Butyl)-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-[2,2'-bipyrimidin]-4-yl)benzenesulf

Bosentan impurity

Bosentan (Benzenesulfonamide)

bosentan , CID 104865

Bosentan, 99%, a endothelin (ET) receptor antagonist

Bosentan 13C6

ro47-0203/039

BOSENTAN

Ro-47-0203, 4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2bipyrimidin]-4-yl]benzenesulfonamide

p-tert-Butyl-N-[6-(2-hydroxyethoxy)-5-(o-methoxyphenoxy)-2-(2-pyrimidinyl)-4-pyrimidinyl]benzenesulfonamide

4-TERT-BUTYL-N-(6-(2-HYDROXYETHOXY)-5-(2-METHOXYPHENOXY)-2,2''-BIPYRIMIDIN-4-YL)BENZENESULFONAMIDE

4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]benzenesulfonamide

4-tert-butyl-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-ylpyrimidin-4-yl]benzenesulfonamide

n-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2-pyrimidin-2-yl-pyrimidin-4-yl]-4-tert-butyl-benzenesulfonamide

4-(1,1-DiMethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-Methoxyphenoxy)[2,2'-bipyriMidin]-4-yl]benzenesulfonaMide

Actelion

Bosentan USP/EP/BP

Bosentan 13C6Q: What is Bosentan 13C6 Q: What is the CAS Number of Bosentan 13C6 Q: What is the storage condition of Bosentan 13C6 Q: What are the applications of Bosentan 13C6

BosentanQ: What is Bosentan Q: What is the CAS Number of Bosentan Q: What is the storage condition of Bosentan Q: What are the applications of Bosentan

benzenesulfonamide, 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-methoxyph 2'- bipyrimidin)-4-yl)-enoxy)( bosentan ro 47-0203 ro 47-0203039 4-(1,1-dimethylethyl)-n-(6-(2-hydroxyethoxy)-5-(2-m

4-(1,1-dimethylethyl)-N-[6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)[2,2'-bipyrimidin]-4-yl]-benzenesulfonamide

147536-97-8

147536-98-8

C27H29N5O6S

Stable Isotopes

Aromatics

Heterocycles

Sulfur & Selenium Compounds

Bases & Related Reagents

Intermediates & Fine Chemicals

Nucleotides

Pharmaceuticals

Free Base API

API

Inhibitors